|
For Immediate Release 21 May 2004
Medical House Plc
Distribution Agreement for new needle-free
insulin delivery system in Pakistan
The Medical House PLC ("TMH"), (AIM:MLH) the orthopaedic
devices and drug
delivery company, announces that it has signed a distribution
agreement
with Venture Pharmaceuticals (Pvt.) Ltd for the distribution of
its needle-free
insulin delivery system (SQ-PEN) in Pakistan.
The World Health Organisation (W.H.O.) estimates that in 2000
there were
some 5.2 million people with diabetes in Pakistan, projecting
this to rise to
15 million by 2030.
The agreement will run on an exclusive basis in Pakistan for
an initial
period of three years.
Venture Pharmaceuticals, a private company based in Karachi,
is an
established medical product distributor which imports and markets
a range of medical goods and pharmaceutical products.
Ian Townsend, Chief Executive, The Medical House PLC, said:
"I am delighted with the latest distribution agreement.
This now gives The
Medical House representation in two of the four largest diabetic
populations in
the world, being China and Pakistan. It also demonstrates the
increasing
global acceptance of needle-free technology as an extremely effective
delivery method for insulin-based pharmaceuticals. It further
proves that our needle-free systems are providing a safe and preferable
alternative for the growing world diabetic population."
- Ends -
Note: Medical House currently has distribution agreements already
in place
for their needle free injection systems for insulin use covering:
Australia;
the Southern Africa Development Communities (including South Africa,
Angola,
Namibia, Botswana, Zambia, Swaziland, Zimbabwe, Malawi, Mozambique
and
Lesotho); Israel; the Benelux countries (Belgium, Holland and
Luxembourg), Turkey; Canada; Egypt, New Zealand, China, Poland
and Pakistan.
For further information
The Medical House PLC
Ian Townsend, Chief Executive Tel: 0114 261 9011
Buchanan Communications
Tim Anderson/Lisa Baderoon/Rebecca Skye Dietrich Tel: 020 7466
5000
Notes to Editors - Market Background
TMH announced in November 2002 that it had received approval from
the PPA
(Prescription Pricing Authority) for the admission of the mhi-500
device
to the NHS Drug Tariff, to be effective from 1 January 2003. This
has enabled the device and the related consumables to be prescribed
on a free of charge
basis to the more than 500,000 people with diabetes in the UK
who inject insulin daily. This makes TMH's device the first needle
free injection system for liquid pharmaceuticals to be available
on the Drug Tariff.
The SQ-PEN is the latest spring powered re-useable needle free
system to
be produced by the Medical House.
This information is provided by RNS
The company news service from the London Stock Exchange
END
|
